StockMarketWire.com - AstraZeneca said the European Commission had approved an update to the marketing authorisation for the company's type-2 diabetes drug to include positive results from a phase 3 drug trial.

In the Phase III DECLARE-TIMI 58 trial, the company's type 2 diabetes drug Forxiga achieved a statistically-significant reduction in the composite endpoint of hospitalisation for heart failure or cardiovascular death versus placebo, one of the two primary efficacy endpoints, AztraZenec said.

There were fewer major adverse cardiovascular events observed with Forxiga for the other primary efficacy endpoint, however this did not reach statistical significance.






Story provided by StockMarketWire.com